Summary
DexCom, Inc. (DXCM) announced preliminary, unaudited financial results for the fourth quarter and full fiscal year 2019, alongside an initial financial outlook for fiscal year 2020. For Q4 2019, the company expects revenue to reach approximately $457 million, representing a significant 35% increase year-over-year. This strong quarterly performance contributes to an anticipated full-year 2019 revenue of approximately $1.470 billion, a growth of over 42% compared to 2018. These results demonstrate robust top-line growth for DexCom, driven by increasing demand for its continuous glucose monitoring (CGM) devices. Looking ahead, DexCom provided its initial financial guidance for fiscal year 2020, projecting total revenue in the range of $1.725 billion to $1.775 billion. This outlook suggests continued strong growth for the company in the upcoming year, likely fueled by ongoing sensor volume expansion and international market penetration. Investors should note that these figures are preliminary and subject to finalization in the company's upcoming Form 10-K filing. The report also includes forward-looking statements regarding future performance, growth in sensor volumes, and international expansion, subject to various risks and uncertainties detailed in previous SEC filings.
Key Highlights
- 1Preliminary Q4 2019 revenue projected at $457 million, up 35% year-over-year.
- 2Full fiscal year 2019 revenue expected to be approximately $1.470 billion, an increase of over 42% compared to 2018.
- 3Initial fiscal year 2020 revenue outlook provided: $1.725 billion to $1.775 billion.
- 4Guidance for FY 2020 indicates continued strong growth momentum for DexCom.
- 5The preliminary results are subject to finalization and audit.
- 6Forward-looking statements address future sensor volume growth and international expansion.